Details for New Drug Application (NDA): 020409
✉ Email this page to a colleague
The generic ingredient in NASAREL is flunisolide. There are twelve drug master file entries for this compound. Two suppliers are listed for this compound. Additional details are available on the flunisolide profile page.
Summary for 020409
Tradename: | NASAREL |
Applicant: | Teva Branded Pharm |
Ingredient: | flunisolide |
Patents: | 0 |
Profile for product number 001
Active Rx/OTC/Discontinued: | DISCN | Dosage: | SPRAY, METERED;NASAL | Strength | 0.029MG/SPRAY | ||||
Approval Date: | Mar 8, 1995 | TE: | RLD: | No |
Expired US Patents for NDA 020409
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
---|---|---|---|---|---|---|---|
Teva Branded Pharm | NASAREL | flunisolide | SPRAY, METERED;NASAL | 020409-001 | Mar 8, 1995 | ⤷ Sign Up | ⤷ Sign Up |
Teva Branded Pharm | NASAREL | flunisolide | SPRAY, METERED;NASAL | 020409-001 | Mar 8, 1995 | ⤷ Sign Up | ⤷ Sign Up |
Teva Branded Pharm | NASAREL | flunisolide | SPRAY, METERED;NASAL | 020409-001 | Mar 8, 1995 | ⤷ Sign Up | ⤷ Sign Up |
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
Complete Access Available with Subscription